CDR-404 by CDR-Life for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

CDR-404 is under clinical development by CDR-Life and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

Pfizer hires Citi analyst Baum to oversee portfolio strategy

Pfizer has tapped Wall Street analyst Andrew Baum to be its new chief strategy and innovation officer, where he’ll head up management of the company’s

May 7, 2024

Risk Adjusted Net Present Value: What is the current valuation of Sandoz Group’s Ustekinumab Biosimilar

The revenue for Ustekinumab Biosimilar is expected to reach an annual total of $285 mn by 2028 globally based off GlobalData’s Revenue Model. The drug’s

November 4, 2023

MedPod Today: ‘Medical Freedom’; More Private Equity Harms; USMLE Cheating Scandal

The following is a transcript of the podcast episode: Rachael Robertson: Hey everybody. Welcome to MedPod Today, the podcast series where MedPage Today reporters share

January 18, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.